JPH04334320A - Composition having intestinal function controlling action - Google Patents

Abstract

PURPOSE:To provide a composition having intestinal function controlling action, containing D-mannose, effective for selectively proliferating bifidus bacteria among enteric bacteria and capable of suppressing the proliferation of bacteria participating in the intestinal putrefaction. CONSTITUTION:D-mannose is administered at a daily dose of about 0.05-1 g per 1kg body-weight to activate the proliferation of bifidus bacteria and suppress the proliferation of bacteria participating in the intestinal putrefaction and fermentation such as bacteroides and E.coli. It is also effective for lowering the pH of feces, lowering the ammonia content in feces and improving the nature of feces. D-mannose is administered by dissolving in drinking water, dissolving in juice, other drink or seasoning or mixing to powdery or solid food.

Description

[Detailed description of the invention]

0001

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition with an intestinal regulation effect, and more particularly to a composition containing D-mannose with an intestinal regulation effect. In the present invention, the intestinal regulating effect is applicable to humans or animals such as pigs, and includes the effect of promoting the growth of bifidobacteria in these animals,
It exhibits the effect of inhibiting intestinal putrefaction and fermentation, reducing the pH of feces, reducing the amount of ammonia in feces, and improving the properties of feces.

0002

[Prior Art] It is well known that intestinal regulating effects can be obtained by improving intestinal bacterial flora (intestinal flora). Among the bacteria that make up the intestinal flora, one of the bacteria that has been pointed out to be useful to humans is Bifidobacterium. Hifidobacterium is well known as a bacterium that makes up the majority of the intestinal bacteria of breast-fed infants. There are many reports on the physiological significance of this bacterium, for example,
It is widely known for its effects on inhibiting putrefaction caused by intestinal putrid bacteria, preventing the production of toxic amines, inhibiting the growth of pathogenic bacteria by producing organic acids such as lactic acid and acetic acid, promoting digestion and absorption, and improving fecal quality. ing.

[0003] The balance among the bacteria that make up the intestinal flora is closely related to health, and when pathogenic bacteria, which are normally suppressed in the minority in the intestine, become dominant, it can lead to pathological conditions. Symptoms are known to occur. Typical examples include the loss of bifidobacteria and diarrhea caused by coliform bacteria and staphylococcus. Based on these findings, it is now believed that a well-balanced intestinal flora is typically one in which Bifidobacteria, which have excellent colonization and proliferation ability in the intestines, are always the most dominant. . Since bifidobacteria have such an effect, various bifidobacterium-containing preparations and dairy products have been developed to increase the number of intestinal bifidobacteria.

On the other hand, sugars are thought to be the most important factors necessary for the growth of bifidobacteria in the intestines, and the effectiveness of lactulose has long been pointed out. Lactulose is an indigestible sugar, and when ingested, it is hardly absorbed into the body and reaches the large intestine, where it is assimilated by intestinal bacteria. However, in addition to Bifidobacteria, the intestines contain a wide variety of intestinal bacteria such as coliforms, Clostridium, and Bacteroides, and lactulose is non-selectively utilized by these intestinal bacteria. However, it was difficult to selectively grow only Bifidobacteria.

[0005]

SUMMARY OF THE INVENTION An object of the present invention is to provide an intestinal regulation effect composition that can selectively proliferate bifidobacteria among intestinal bacteria.

[0006]

[Means for Solving the Problems] As a result of extensive research into sugar sources that selectively proliferate Bifidobacteria in the intestine, the present inventors have found that D-mannose has been found to be effective against bacteria such as Bacteroides and coliform bacteria in the intestine. discovered that it suppresses the growth of bacteria involved in intestinal putrefaction fermentation and activates the growth of bifidobacteria.

At the same time, the effects of lowering the pH of feces, lowering the amount of ammonia in feces, and improving the properties of feces were also observed. The present invention is based on such a discovery, and is effective as a substance that has intestinal regulation effects, including the effect of increasing bifidobacteria in the intestines of animals including humans. The intestinal regulating effect appears depending on the amount of D-mannose, but preferably the intake amount is about 0.05 to 1 g per 1 kg of body weight per day.

[0008] D-mannose can be ingested or administered in any desired form such as liquid, powder, capsule, or tablet. Further, the above-mentioned forms can be used as they are for the purpose of the present invention, or they can be dissolved in water and used as drinking water. Further, it may be dissolved in juice, other drinks, or seasonings, and furthermore, it may be mixed with powder or solid foods for use. For animals, it can also be used by adding the desired amount to feed or drinking water.

[0009] D-mannose used in the present invention is widely used in foods as a natural additive sweetener for food processing and is safe (Supervised by Akio Toyama, Natural Products Handbook, Vol. 56 pages, published on July 1, 1971. Shokuhin to Kagakusha Publishers.)

0010

[Example] Furthermore, the time of intake is not particularly limited and may be any normal intake time. EXAMPLES The present invention will be specifically explained below with reference to Examples.

[0011]

[Example 1] Analysis of intestinal flora upon ingestion of D-mannose [Test method] <Method of ingesting D-mannose and collection of feces> Subjects were 6 healthy adults (3 men and 3 men: 26-38 years old) An administration test was conducted. The test schedule consisted of ingesting a beverage containing 10 g of D-mannose in approximately 150 cc of coffee once a day after lunch for 4 consecutive days, and collecting feces before, during, and one week after stopping the intake. The feces were used as samples.

[0012] From one week before the collection of feces until the end of the test, the subjects stopped ingesting foods containing lactose and lactic acid bacteria such as milk and fermented milk, drugs, natto, and alcohol. <Measurement of intestinal flora> The collected samples were collected using Mitsuoka's method (Bifidobacteria Microflo
Intestinal flora was analyzed according to RA 1:3-24 (1982)). The isolation medium uses a combination of 3 types of non-selective media and 10 types of selective media to search for a wide variety of bacteria in the intestine, and the non-selective medium is used to isolate the most dominant bacteria in the intestine. (Table 1).

[0013]

[Table 1]

[0014] In use, add 1 g of feces to 9 ml of dilution medium, make a 10-1 dilution, and sequentially dilute 10
While carrying out serial dilution, the separation medium is divided into 1/3 and 1/4 areas as necessary, and EG and BL agar media are divided into 10-6 and 10-6
-7, 10-8 dilutions were added to TS agar medium at 10-5, 1
0-6, 10-7 dilutions, also TATAC, DH
L, PEES, P, BS, ES, NBGT, NN, V
S, LBS agar medium contains 10-1, 10-3, 10-
5. Drop 0.05ml of each of the 10-7 dilutions,
The mixture was applied uniformly with a Conrage rod and cultured at 37°C for 2 to 3 days. After culturing, the colonies that appeared were counted and subjected to Gram staining and microscopic examination to identify enteric bacteria. [Results] Table 2 shows specific changes in the intestinal bacteria group when D-mannose was ingested. (Only bacteria detected in all test subjects are displayed). Among these intestinal bacteria, variations were observed in three types of bacteria: Bifidobacteria, Coliforms, and Bacteroides. The state of those fluctuations is shown in FIGS. 1 to 3. In both cases, total bacterial count (logarithm)/
It is shown as the average value of g feces.

Table 2 and FIG. 1 show that the composition of the present invention promotes the growth of bifidobacteria in the intestine, and as shown in FIGS. A decrease in the number of bacteria was observed.

[0016]

[Table 2]

These results show that administration of D-mannose to humans is effective in promoting the growth of bifidobacteria and inhibiting intestinal putrefaction fermentation.

[0018]

[Example 2] Measurement of fecal pH, ammonia amount, and water content when D-mannose was ingested [Test method] <D-mannose ingestion method and fecal collection> Six healthy adults (3 men and 3 men each) An administration study was conducted on subjects aged 26 to 38 years old. The test schedule consisted of ingesting a jelly made by mixing 10 g of D-mannose with commercially available jelly powder once a day after lunch for 4 consecutive days, and collecting feces before, during, and one week after stopping intake. The feces were then used as samples.

[0019] From one week before the collection of feces until the end of the test, ingestion of foods containing lactose and lactic acid bacteria such as milk and fermented milk, drugs, natto, and alcohol was discontinued. [Results] The pH, ammonia content, and water content of feces during the D-mannose administration period are shown in FIGS. 4 to 6. During the administration period, fecal pH decreased (Figure 4). In addition, the content of ammonia in feces, which is considered a powerful indicator of intestinal putrefaction, decreased (Figure 5). The water content varied by 72-87% before administration, but converged to around 84% during administration (Figure 6).

[0020] From the results of the above examples, it is clear that when the composition containing D-mannose has an intestinal regulating effect, the colonization of bifidobacteria in the intestines is promoted and an environment is created in which they can proliferate. It turns out that this is possible. At the same time, a decrease in bacterial species involved in intestinal putrefaction, such as Bacteroides and coliforms, was observed, and fecal ammonia content, which is considered a strong indicator of intestinal putrefaction, also decreased. From these results, administration of an intestinal regulating composition containing D-mannose to humans or animals such as pigs is effective in improving intestinal flora and suppressing intestinal putrefaction and fermentation. it is conceivable that.

[0021] Furthermore, since the properties of feces are also improved,
It is also thought to be effective in treating and preventing diarrhea and constipation.

[0022]

[Effects of the Invention] According to the intestinal regulation effect composition of the present invention,
Among intestinal bacteria, Bifidobacterium can be selectively grown, and the growth of bacterial species involved in intestinal putrefaction can be inhibited, thereby providing excellent intestinal regulation effects.

[Brief explanation of the drawing]

FIG. 1 is a diagram showing changes in Bifidobacteria.

FIG. 2 is a diagram showing changes in coliform bacteria.

FIG. 3 is a diagram showing the variation of Bacteroidetes.

FIG. 4 is a diagram showing changes in pH of feces.

FIG. 5 is a diagram showing changes in fecal ammonia concentration.

FIG. 6 is a diagram showing changes in fecal moisture content.

Claims (1)

[Claims] 1. A composition with an intestinal regulating effect, characterized by containing D-mannose.